Men’s health

  • Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.
  • Practice-changing research shows that a combination of androgen deprivation therapy — a commonly used hormone injection — plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients' prostate cancer at bay for five years.
  • Investigators have discovered that tumor cells use mitochondria to control their growth and detect stress that can destroy a tumor cell if it is not controlled.
  • Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer. Now, researchers have found that while these efforts have been effective, the incidence of higher-grade disease and metastasis at diagnosis have risen.
  • Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures. These molecules may be used as single or combination therapy for patients with advanced disease to prevent and treat metastatic spread.